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Abstract
Background: Bone forming metastases are a common and disabling consequence of prostate cancer (CaP). The potential
role of osteoclast activity in CaP bone metastases is not completely explained. In this study, we investigated ex vivo whether
the osteolytic activity is present and how it is ruled in CaP patients with bone forming metastases.
Methodology: Forty-six patients affected by newly diagnosed CaP and healthy controls were enrolled. At diagnosis, 37
patients had a primary tumour only, while 9 had primary tumour and concomitant bone forming metastases. In all patients
there was no evidence of metastasis to other non-bone sites. For all patients and controls we collected blood and urinary
samples. We evaluated patients’ bone homeostasis; we made peripheral blood mononuclear cell (PBMC) cultures to detect
in vitro osteoclastogenesis; we dosed serum expression of molecules involved in cancer induced osteoclatogenesis, such as
RANKL, OPG, TNF-alpha, DKK-1 and IL-7. By Real-Time PCR, we quantified DKK-1 and IL-7 gene expression on micro-
dissected tumour and healthy tissue sections.
Principal Findings: CaP bone metastatic patients showed bone metabolism disruption with increased bone resorption and
formation compared to non-bone metastatic patients and healthy controls. The CaP PBMC cultures showed an enhanced
osteoclastogenesis in bone metastatic patients, due to an increase of RANKL/OPG ratio. We detected increased DKK-1 serum
levels and tissue gene expression in patients compared to controls. IL-7 resulted high in patients’ sera, but its tissue gene
expression was comparable in patients and controls.
Conclusions: We demonstrated ex vivo that osteoclastogenesis is an active mechanism in tumour nesting of bone forming
metastatic cancer and that serum DKK-1 levels are increased in CaP patients, suggesting to deeply investigate its role as
tumour marker.
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Introduction
Prostate cancer (CaP) is the second leading cause of cancer-
related deaths in men [1]. A typical feature of CaP is the ability to
metastatize to the bone, as more than 80% of men who died for
CaP developed bone metastases [2]. Growth of CaP within bone
promotes primarily osteoblastic lesions with underlying osteolytic
areas [1]. In physiological conditions osteoclast (OC) and
osteoblast activity is well balanced, but in pathologic condition
this equilibrium (bone homeostasis) is disrupted. The role of OCs
in osteolytic metastases has been clearly demonstrated, and it has
been suggested that OCs might play an important role in the
osteoblastic metastases as well. Interactions among CaP cells,
osteoblasts and OCs suggest that bone tropism might be caused by
tumour dependence on one or more osteoblast/OC–derived
factors for cancer cell growth and maintenance [3].
We previously demonstrated that patients with osteolytic bone
metastases from different solid tumours showed enhanced
spontaneous osteoclastogenesis, due to increased T cell release of
pro-osteoclastogenic factors, such as TNF-alpha, IL-7 and
RANKL [4]. The role of OPG/RANKL axis in the osteolytic
component of CaP-mediated bone metastases has been elucidated
[5], while TNF-alpha and IL-7 possible functions in CaP bone
lesions remain unclear.
Other key factors in bone biology are WNTs, a family of small
secreted glycoproteins, which inhibits OC differentiation [6],
stimulates osteoblastogenesis and mineralizing activity of osteo-
blasts [7]. The activity of WNT family is antagonized by several
secreted factors such as dickkopf (DKK) proteins. Recent data
reported DKK-1 expression in some human specimens of
tumours, suggesting that a cancer-mediated modulation of WNT
activity influences the metastatic phenotype [8,9].
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This cross-sectional investigation was designed to study how
bone forming metastases by CaP affects bone turnover, OC
formation by peripheral blood mononuclear cells (PBMC), and the
production of osteoclastogenic and anti-osteoclastogenic factors in
patients affected by bone metastatic CaP.
We report an increased osteoclastogenesis in CaP bone metastatic
patients, due to an increase in the serum RANKL/OPG ratio,
suggesting that enhanced OC formation plays an active role in bone
forming metastases. We detected high DKK-1 serum levels and
gene expression in CaP patients compared to healthy controls.
Results
Bone turnover is increased in bone metastatic patients
The markers of bone turnover were higher in patients with bone
metastases compared to non-bone metastatic patients and healthy
controls (Table 1). In detail, CaP patients did not show significant
differences in bone density, but had higher PTH, BAP, BGP,
TRAPC5b and crosslink levels than healthy controls. These results
confirm the disruption in bone homeostasis with increased bone
resorption and formation in metastatic patients.
Osteoclastogenesis is increased in CaP bone metastases
To evaluate whether the enhancement of bone resorption in
metastatic patients is due to an increase in OC formation, we
examined the ability of in vitro PBMCs to spontaneously
differentiate in OCs in patients with or without bone metastases
and in healthy controls.
The OC differentiation was demonstrated by the presence of
multinucleated/TRAP positive cells from cancer patient and
healthy control PBMCs (Fig. 1A–C). As showed in Fig. 1D the
number of OCs was significantly higher in bone metastatic patients
(mean6se, 216.22639.55) than in patients without bone metastases
(112.71614.76) and in healthy controls (73.55611.69), p,0.001.
RANKL/OPG ratio is increased in metastatic patients
In order to investigate the factors responsible for the increased
osteoclastogenesis in patients, we dosed the serum levels of TNF-
alpha, RANKL and OPG. The TNF-alpha serum levels were not
significantly different among the three groups (data not shown),
while we observed a significantly increased ratio RANKL/OPG in
bone metastatic sera (19.6266.52) compared to non-metastatic
patients (5.4862.48) and healthy controls (6.8962.6), p,0.03.
IL-7 serum level is increased in cancer patients
We measured IL-7 serum levels in patients and controls. Serum
IL-7 levels were significantly higher in bone metastatic patients
(mean6se, 19.8662.01 pg/ml) than in healthy controls
(7.0761.27 pg/ml), p,0.001. We dosed comparable IL-7 levels
in non-bone metastatic (19.7563.55 pg/ml) and bone metastatic
patients (19.8662.01 pg/ml), (Fig. 2A). This result led us to
investigate whether tumor cells were responsible for the increase of
IL-7 production; therefore we examined the quantitative IL-7
expression in CaP and in healthy prostate tissues. Tumour cells
expressed low and comparable levels of IL-7 in patients and
healthy controls (Fig. 2B). This suggests that the increased
circulating IL-7 might depend on the production by the immune
system cell, such as T and B lymphocytes [4].
DKK-1 expression is higher in CaP patients
Literature data reported that DKK-1 is involved in bone
homeostasis [8]. We dosed DKK-1 serum level in CaP patients
and healthy controls. CaP patients showed higher DKK-1 levels
than healthy controls, p,0.004 (Fig. 3A). To evaluate whether or
not DKK-1 is produced by cancer tissues, we studied its expression
on CaP and healthy tissues by RQ-PCR. Our data demonstrated
that CaP tissue expressed significantly more DKK-1 than healthy
tissue, p,0.001 (Fig. 3B).
Discussion
Prostate cancer frequently develop bone forming metastases;
nonetheless a brisk osteolytic activity is present in metastatic
compared to non-metastatic patients [10]. The mechanisms through
which CaP promotes aberrant bone remodelling are not clearly
defined. The disclosure of tumour nesting in bone might provide new
tools for an early diagnosis of bone metastases and suggest novel
therapeutic regimens for the control of CaP progression. The aim of
our study was to investigate how the osteolytic component of bone
metastasis affects bone turnover, OC formation by PBMC, and the
production of osteoclastogenic and anti-osteoclastogenic factors in
patients affected by bone metastatic CaP.
Table 1. Characteristics of patients and healthy controls.
Patients without
bone metastases (37)
Patients with
bone metastases (9)
Healthy
controls (20) p
Age (yrs) 6467 67610 6066 NS
BMI 25.962.4 25.962.4 25.462.3 NS
Lumbar BMD (g/cm2) 1.0260.1 1.0660.1 1.0360.2 NS
Femoral neck BMD (g/cm2) 0.7360.1 0.7560.1 0.7660.1 NS
PTH (pg/ml) 50.15622.6 69.8634.3* 34.4615.9 0.018
Calcium (mEq/L) 4.660.2 4.261 4.660.2 NS
Phosphate (mMol/L) 1.0260.1 1.1360.1 1.0760.2 NS
BAP (UI/L) 11.6166.4 55.5621.8* 10.764.4 0.001
BGP (ng/ml) 4.662.4 19.668.9* 5.0062.2 0.000
TRAP5b (U/L) 2.160.4 7.866.5* 2.460.6 0.001
Cross links (nM/mM creat) 5.4961.5 15.464.1* 6.763.3 0.001
Bone turnover marker values are shown as mean6SD, the p values were calculated by one way ANOVA and the Bonferroni post-hoc correction. * and u indicates the
values significantly different between patients with/ without bone metastases (* p=0.001, u p=0.000).
doi:10.1371/journal.pone.0003627.t001
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In the selection of CaP cases, we decided to avoid patients with
an advanced metastatic disease, since therapeutic regimens might
represent a bias for our analysis. In this study, we have an
imbalance between the bone and non-bone metastatic patients’
number, which depends on the presence of a smaller amount of
bone metastatic compared to non-bone metastatic CaP patients at
diagnosis [3]. In fact, in the natural history of the disease, bone
metastases are a frequent, but late event [11].
The bone turnover was enhanced in bone metastatic patients, in
particular we observed both an increase in bone formation and
resorption markers. PTH level was slightly increased in bone
metastatic patients compared to healthy controls, according to
PTH ability to promote the growth and invasiveness of prostate
cancer cells in bone [12].
The observed increase in bone resorption and the previously
demonstrated spontaneous osteoclastogenesis in cancer patients
with osteolytic metastases [13] prompted us to investigate
osteoclastogenesis from CaP patients’ PBMC in vitro. OC
formation was higher in bone metastatic patients compared to
both non-bone metastatic patients and healthy controls. To
identify the factors responsible for the increase in OC formation,
we measured molecules mostly involved in osteoclastogenesis, such
as TNF-alpha, RANKL, OPG, IL-7 and DKK-1. The TNF-alpha
serum levels were not significantly increased in CaP patients,
differently from other bone metastatic tumours, where TNF-alpha
plays an important role in osteoclastogenesis [14]. Otherwise the
RANKL/OPG ratio was higher in bone metastatic patients,
explaining the increased osteoclastogenesis and according to
previous literature data [15].
The interplay among the tumour cells, the immune system and
the bone tissue has become a relevant object of intensive study.
Since IL-7 involvement in bone metastasis was previously
demonstrated in other tumours [4,16], we investigated this issue
showing an increase in serum IL-7 levels in CaP patients with and
without bone lesions. The increase of IL-7 might account for the
RANKL/OPG augment, since IL-7 stimulates RANKL production
from T cells [17]. We evaluated IL-7 gene expression in CaP and
normal prostate tissues, showing comparable IL-7 expression in
prostate cancer and normal tissues. This result differs from our
published data on lung cancer, where the tumour tissue expressed
higher IL-7 levels compared with the normal counterpart [18]. We
suggest that this discrepancy might be due to the different tumour
type and bone metastatic behaviour, as lung cancer causes osteolytic
metastases, while CaP produces mainly bone forming lesions. The
increased IL-7 serum level may depend on immune system
activation against the tumour. In fact, it has been previously
demonstrated that T and B cells produce IL-7, in both tumours and
other pathologies associated to bone resorption [4,19,20]. WNT
signalling plays an important role in bone development, since it
inhibits OC differentiation [6], stimulates osteoblastogenesis and
mineralizing activity of osteoblasts [7]. WNT proteins are also
expressed by CaP and can promote tumour bone invasion [21].
DKK is a soluble inhibitor of canonical WNT signalling [22]. A
recent study associates DKK-1 expression in breast cancer with the
presence of bone metastases [23]. Data regarding DKK-1
expression in CaP are scant: some authors report an increase
DKK-1 expression in osteolytic lesions, but not in the primary
tumours [8]. Hall et al reported that CaP-derived DKK-1 is involved
Figure 1. Analysis of osteoclastogenesis from CaP patients’ PBMCs. TRAP positive multinucleated cells were identified as OCs and counted,
in both patients and healthy controls cultures, (A). The OC number in bone metastatic patients was significantly higher than in non-bone metastatic
patients, p,0.004 and in healthy controls, p,0.001 (B).
doi:10.1371/journal.pone.0003627.g001
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in osteoblastic activity in bone metastases, since DKK-1 signalling
might account for switching the bone response to CaP cells from
osteolytic to osteoblastic and vice versa [24]. In this work, we studied
only patients with bone forming metastases, therefore we are unable
to correlate osteolytic activity induced by CaP cells and DKK-1
expression, as previously described [8]. Nonetheless, we found a
large amount of DKK-1 in serologic samples from cancer patients
and an enhanced DKK-1 gene expression in CaP tissues, suggesting
that the increased serum DKK-1 levels in CaP patients might
depend on the CaP cell secretion. This result will be deeply study in
order to evaluate the potential role of DKK-1 as tumour marker in
CaP. Moreover, we could speculate that CaP cells stimulate bone
marrow environment to increase the DKK-1 release through
unknown mechanisms. In our bone metastatic patients, serum
DKK-1 levels are slightly increased compared to non-metastatic
patients, without a statistically significant difference. This could
depend on our low number of patients, but investigating a large
number of patients, we expect to show a difference between the two
groups, confirming the literature data [23].
Materials and Methods
Patients and markers of bone turnover
The experimental project and all the studies performed on the
patients were approved by the Ethical Committee of our
Institution (Azienda Ospedaliera–Universitaria San Giovanni
Battista in Torino) and written informed consent from patients
and healthy controls was obtained. The studied population
included 46 patients affected by newly diagnosed CaP (37 had a
primary tumour only, while 9 had primary tumour and
concomitant bone forming metastases) and 20 healthy men. In
all patients there was no evidence of metastasis to other non-bone
sites. It has been demonstrated that estrogen loss significantly
affect osteoclast formation [25]. Thus we studied CaP that, being
an only male tumour, avoids by default all the possible biases due
to the cyclical estrogen variations and postmenopausal fall in
estrogen levels in females. Patients and controls were matched for
age and body mass index. Bone mineral density (BMD) was
measured by double-emission X-ray absorptiometry with a
Hologic QDR 4500 at lumbar spine and femoral neck both in
patients and controls. Subjects with intestinal malabsorption
diseases, other kind of deficient nutritional status, secondary
osteoporosis or taking drugs active on bone turnover or anti cancer
therapy were excluded. The presence of bone metastases was
confirmed using 99Tc bone scanning and further imaging studies
according to the standard clinical practice.
In order to investigate bone metabolism status, patients and
controls were subjected to analysis of standard clinical markers of
Figure 2. IL-7 expression by CaP. IL-7 serum levels in patients with/
without bone metastases and in healthy controls were measured by
ELISA. Bone metastatic (p,0.01) and non-bone metastatic patients
(p,0.03) had significantly higher IL-7 serum levels compared to healthy
controls (A). CaP and healthy tissues were analyzed by Real-Time PCR in
order to quantify IL-7 gene expression. The IL-7 quantization was
expressed as IL-7 on b-Actin (the control gene) plasmid copy number.
The histogram showed comparable IL-7 expression levels in CaP and
healthy tissues.
doi:10.1371/journal.pone.0003627.g002
Figure 3. DKK-1 expression is higher in CaP patients. DKK-1
levels were dosed in serum patients with/without bone metastases and
in healthy controls by ELISA. Bone metastatic (p,0.004) and non-bone
metastatic patients (p,0.01) had significantly higher DKK-1 serum
levels compared to healthy controls (A). CaP and healthy tissues were
analyzed by Real-Time PCR in order to quantify DKK-1gene expression.
The DKK-1 quantization was expressed as DKK-1 on b-Actin (the control
gene) plasmid copy number. The histogram showed higher DKK-1
expression levels in CaP than in healthy tissues, p,0.001 (B).
doi:10.1371/journal.pone.0003627.g003
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bone metabolism, such as serum PTH, bone alkaline phosphatase
(BAP), calcium, phosphate, osteocalcin (BGP) and urinary
deoxypyridinoline (urinary crosslinks) [26]. In particular, crosslinks
dosage has been chosen in clinical practice to monitor bone
metastatic disease and the response to anti-resorbing treatments
such as bisphosphonates [27,28]. As markers of bone resorption
we also measured Tartrate Resistent Acid Phosphatase 5b
(TRAP5b) in sera [29], by BoneTRAP ELISA kit (Suomen
Bioanalytiikka Oy, Turku, Fin). Serological markers, such as PSA
and histological grading, according to Gleason, were recorded for
all the patients included in this study [30,31]. All biochemical
measurements were performed on a single blood or urinary sample
at a single time point per subject.
Cell cultures
As previously described [13], for all patients and healthy
controls, PBMCs were isolated from peripheral blood and cultured
in a-MEM, supplemented with 10% FBS, penicillin 100 U/ml
and streptomycin 100 mg/m (Cambrex, Bio Science, Walkersville,
MD), without adding exogenous stimulatory factors such as M-
CSF and RANKL. After 15 days, cultures were stopped, mature
OCs were identified as multinucleated cells containing three or
more nuclei and positive for TRAP expression (Sigma Aldrich, St.
Louis, MO).
Cytokines dosage
In order to evaluate factors involved in osteoclastogenesis the
amount of serum total RANKL (free and OPG-bound), OPG,
TNF-alpha, IL-7 and DKK-1 were determined by commercially
available ELISA kit according to manufacturer’s instructions.
Samples were assayed in duplicate and data were expressed as
mean values. The sensitivities were: 1.56 to 30000 pg/ml for total
RANKL (Apotech Corporation, Epalinges, CH); 0 to 4000 pg/ml
for OPG; 0.12 to 32 pg/ml for TNF-alpha; 0.1 to 16 pg/ml for
IL-7 (R&D system, Abingdon, UK) and 0.38 to 50 pmol/L for
DKK-1 (Biomedica, Wien, A).
RNA extraction from formalin-fixed, paraffin-embedded
(FFPE) CaP tissues
We extracted RNA from FFPE CaP and healthy tissues. For 19
patients, we obtained samples from tumour and healthy tissue
blocks, the tumour areas were selected on the haematoxylin/eosin
sections by microscope and manually dissected. RNA was isolated
from FFPE CaP tissue block (10 mm sections) using the RecoverAll
Total Nucleic Acid Isolation Kit (Ambion, Huntingdon, UK). 1 mg
of RNA was converted up to single stranded cDNA by the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Warrington, UK).
Generation of patient plasmid standard
PCR primers for IL-7, DKK-1 and b-Actin were designed using
Primer Express v2.0 software and synthesized by Applied
Biosystems (Warrington, UK). The IL-7 and b-Actin sequences
were previously published [18], while the DKK-1 sequences were:
sense 59-GGAAGCGCCGAAAACG-39 and antisense 59-ACA-
CACATATTCCATTTTTGCAGTA-39. Purified fresh PCR
products of 80-bp for IL-7, 75-bp for DKK-1 and 78-bp for b-
Actin were directly cloned using TA Cloning Kit Dual Promoter
(Invitrogen, Carlsbad, CA) as previously described [18]. Positive
clones were sequenced to confirm their identity. 10 mg of the
selected plasmid for the genes were digested with 8 U of Hind III
restriction enzyme overnight at 37uC. Linearized plasmids were
finally purified with NucleoSpin clean up extraction kit (Ma-
cherey-Nagel, Du¨ren, D), resuspended with 16 TE and OD260
was determined. Copy number was calculated from the plasmid
concentration, mean molecular weight of the nucleotides (660 g/
Mol) and plasmid plus insert length.
Real-Time Quantitative analysis of IL-7 and DKK-1 gene
expression
Considering the higher amount of serum IL-7 and DKK-1 in
CaP patients both with and without bone metastases, we decided
to investigate whether these factors are produced by tumor cells.
We performed quantitative analysis of IL-7 and DKK-1
expression by Real-Time Quantitative PCR (RQ-PCR), b-Actin
was the housekeeping control. RQ-PCR analysis of IL-7 and
DKK-1 was carried out using the iCycler iQTM system (Bio Rad,
Hercules, CA, USA). TaqMan probes were designed using Primer
Express v2.0 software and synthesized by Applied Biosystems
(Warrington, UK). IL-7 and b-Actin specific TaqMan probes were
previously used [18], while the DKK-1 probe was (59-ATGCGT-
CACGCTATGTGCTGCC-39). All the probes were labelled at
the 59 end with 6-carboxy fluorescein (FAM) and the 39 end with
6-carboxy-tetrametil rhodamine (TAMRA). Reactions for IL-7,
DKK-1 and b-Actin quantification were performed in a 25 ml final
volume with 2 ml of sample cDNA, 16 iQ Supermix (Bio Rad,
Hercules, CA, USA), 0,3 mM of each primer and 0,4 mM of the
probes. PCR primers were the same used for IL-7, DKK-1 and b-
Actin cloning. The amplification conditions for quantization were:
95uC for 15 minutes, 50 cycles at 95uC for 15 seconds, 58uC for
IL-7, 60uC for DKK-1 and b-Actin for 1 minute.
Statistical analyses
Statistical analyses were performed by the Statistical Package for
the Social Sciences (spssx/pc) software 15.0 (SPSS, Chicago, IL,
USA). Continuous variables were expressed as mean and standard
deviation. In order to compare patients both with and without
bone metastases and controls, we performed a one way analysis of
variance (ANOVA). Bonferroni correction was carried out for
multiple comparisons. To explore the effect of the continuous
variables analysed on OC formation, we fitted a linear regression
model by step way procedure. The gene expression of DKK-1 and
IL-7 was compared between tumour and healthy tissue by paired
Student’s T test. The results were considered statistically
significant for p,0.05.
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